Clinical trial
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major…
NCT00130676 · Corcept Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00130676 |
|---|---|
| Title | A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of CORLUX™ (Mifepristone) in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features |
| Lead sponsor | Corcept Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder, Psychotic Disorders |
| Intervention type | Drug |
| Interventions | Mifepristone, matching placebo |
| Enrollment | 257 |
| Start date | Sep 1, 2004 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Aug 16, 2005 |
| Last update posted | Feb 15, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: